For research use only. Not for therapeutic Use.
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer’s disease research[1][2].
| Catalog Number | I001725 |
| CAS Number | 481629-87-2 |
| Synonyms | 2-[1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)indol-3-yl]-2-oxoacetic acid |
| Molecular Formula | C28H27NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H27NO3/c1-18-6-5-7-20(14-18)21-10-13-25-23(15-21)24(26(30)27(31)32)17-29(25)16-19-8-11-22(12-9-19)28(2,3)4/h5-15,17H,16H2,1-4H3,(H,31,32) |
| InChIKey | HSXLMAFNWCSZGP-UHFFFAOYSA-N |
| SMILES | CC1=CC(=CC=C1)C2=CC3=C(C=C2)N(C=C3C(=O)C(=O)O)CC4=CC=C(C=C4)C(C)(C)C |
| Reference | [1]. Zhao J, Pei G. Evoking plasmin for beta-amyloid clearance. Cell Res. 2008 Aug;18(8):803-4. [2]. Kellici TF, Pilka ES, Bodkin MJ. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19. Trends Pharmacol Sci. 2021 Jun;42(6):431-433. |
